Remodulin vs Tyvaso
Side-by-side cost comparison based on Medicare Part D data
Remodulin
Treprostinil (SC/IV)
Manufactured by United Therapeutics
Tyvaso
Treprostinil (inhaled)
Manufactured by United Therapeutics
Tyvaso costs 31% less per claim than Remodulin ($14,349.00 vs $20,857.00). A generic version of Tyvaso is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Remodulin | Tyvaso |
|---|---|---|
| Avg Cost Per Claim | $20,857.00 | $14,349.00 |
| Total Medicare Spending | $876.0M | $1.2B |
| Total Beneficiaries | 4,800 | 8,400 |
| Total Claims | 42,000 | 86,000 |
| Annual Cost/Patient | $182,500.00 | $146,905.00 |
| Year-over-Year Change | +8.6% | +24.6% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | United Therapeutics | United Therapeutics |
| Condition | Pulmonary Hypertension | Pulmonary Hypertension |
| Generic Name | Treprostinil (SC/IV) | Treprostinil (inhaled) |
Remodulin vs Tyvaso: What the Data Shows
Remodulin (Treprostinil (SC/IV)) and Tyvaso (Treprostinil (inhaled)) are both used to treat pulmonary hypertension. Based on Medicare Part D data, Tyvaso costs $14,349.00 per claim, which is 31% less than Remodulin at $20,857.00 per claim.
Medicare spent $876.0M on Remodulin and $1.2B on Tyvaso. In terms of patient reach, Tyvaso serves more beneficiaries (8,400 vs 4,800).
Year-over-year spending changed +8.6% for Remodulin and +24.6% for Tyvaso. Tyvaso saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Tyvaso is cheaper at $14,349.00 per claim, compared to $20,857.00 for Remodulin. That makes Tyvaso about 31% less expensive per claim based on Medicare Part D data.
Yes, both Remodulin and Tyvaso are used to treat pulmonary hypertension. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Treprostinil (SC/IV) and generic Treprostinil (inhaled) can offer significant cost savings, typically 80-95% less than the brand name.
Medicare Part D spent $876.0M on Remodulin covering 4,800 beneficiaries, and $1.2B on Tyvaso covering 8,400 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
Comparing Remodulin and Tyvaso on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.